Impact of
IL-10
Laryngeal squamous cell carcinoma
gene polymorphism
levels
rs1800871
rs1800872
rs1800896
serum
survival rate.
Journal
Cancer genomics & proteomics
ISSN: 1790-6245
Titre abrégé: Cancer Genomics Proteomics
Pays: Greece
ID NLM: 101188791
Informations de publication
Date de publication:
Historique:
received:
16
11
2020
revised:
02
12
2020
accepted:
17
12
2020
entrez:
9
1
2021
pubmed:
10
1
2021
medline:
21
8
2021
Statut:
ppublish
Résumé
Prognosis of advanced stages of laryngeal squamous cell carcinoma (LSCC) remains poor. To clarify therapeutic targets and improve survival rate, identification of new specific and prognostic biomarkers of LSCC is required. The study aimed to evaluate the impact of IL-10:rs1800871, rs1800872, rs1800896 single nucleotide polymorphisms (SNPs), and IL-10 serum levels on LSCC development and determine associations of selected SNPs with patient survival rate. A total of 300 LSCC patients and 533 controls were included in the study. Genotyping was carried out using RT-PCR; IL-10 serum levels were analyzed by ELISA. Significant associations were identified between IL-10 rs1800871 variants and advanced stage of LSCC patient group in the codominant, recessive and additive models (OR=0.473, p=0.027; OR=0.510, p=0.040; and OR=0.733; p=0.037). Significant variants of IL-10 rs1800872 were determined in the codominant, recessive and additive models (OR=0.473, p=0.027; OR=0.510, p=0.040; and OR=0.733, p=0.037). The distribution of IL-10 SNPs genotypes did not impact LSCC patient survival rate (respectively, p=0.952; p=0.952; p=0.991). IL-10:rs1800871 and rs1800872 SNPs are associated with advanced stage of LSCC. The genotypic distribution of IL-10 SNPs does not influence the survival rate of LSCC patients.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
Prognosis of advanced stages of laryngeal squamous cell carcinoma (LSCC) remains poor. To clarify therapeutic targets and improve survival rate, identification of new specific and prognostic biomarkers of LSCC is required. The study aimed to evaluate the impact of IL-10:rs1800871, rs1800872, rs1800896 single nucleotide polymorphisms (SNPs), and IL-10 serum levels on LSCC development and determine associations of selected SNPs with patient survival rate.
PATIENTS AND METHODS
METHODS
A total of 300 LSCC patients and 533 controls were included in the study. Genotyping was carried out using RT-PCR; IL-10 serum levels were analyzed by ELISA.
RESULTS
RESULTS
Significant associations were identified between IL-10 rs1800871 variants and advanced stage of LSCC patient group in the codominant, recessive and additive models (OR=0.473, p=0.027; OR=0.510, p=0.040; and OR=0.733; p=0.037). Significant variants of IL-10 rs1800872 were determined in the codominant, recessive and additive models (OR=0.473, p=0.027; OR=0.510, p=0.040; and OR=0.733, p=0.037). The distribution of IL-10 SNPs genotypes did not impact LSCC patient survival rate (respectively, p=0.952; p=0.952; p=0.991).
CONCLUSION
CONCLUSIONS
IL-10:rs1800871 and rs1800872 SNPs are associated with advanced stage of LSCC. The genotypic distribution of IL-10 SNPs does not influence the survival rate of LSCC patients.
Identifiants
pubmed: 33419896
pii: 18/1/53
doi: 10.21873/cgp.20241
pmc: PMC7796822
doi:
Substances chimiques
IL10 protein, human
0
Interleukin-10
130068-27-8
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
53-65Informations de copyright
Copyright© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
Dis Markers. 2005;21(3):157-65
pubmed: 16276011
J Endocrinol Invest. 2008 Sep;31(9):750-4
pubmed: 18997484
PLoS One. 2015 Oct 06;10(10):e0139598
pubmed: 26440936
Immunogenetics. 1997;46(2):120-8
pubmed: 9162098
Bioessays. 2013 Jul;35(7):623-31
pubmed: 23666891
Asian Pac J Cancer Prev. 2018 Dec 25;19(12):3353-3359
pubmed: 30583340
Laryngoscope. 2015 Jul;125(7):1667-74
pubmed: 25694265
Kidney Blood Press Res. 2017;42(1):89-98
pubmed: 28359052
J Occup Environ Med. 2012 Jan;54(1):71-84
pubmed: 22157731
Cancer Lett. 2015 Oct 28;367(2):103-7
pubmed: 26188281
Cytokine. 2018 Nov;111:230-236
pubmed: 30195978
J Laryngol Otol. 2017 May;131(5):455-461
pubmed: 28294085
Lancet. 1973 Aug 25;2(7826):416-7
pubmed: 4124894
Iran J Immunol. 2014 Dec;11(4):259-68
pubmed: 25549593
J Leukoc Biol. 2005 Nov;78(5):1043-51
pubmed: 16204623
J Appl Genet. 2018 Aug;59(3):301-304
pubmed: 29705927
Anticancer Res. 2020 Apr;40(4):2003-2009
pubmed: 32234890
Anticancer Res. 2017 Aug;37(8):4399-4403
pubmed: 28739733
Cancer Invest. 2001;19(3):239-47
pubmed: 11338880
Cancer Biol Ther. 2020 Apr 2;21(4):372-378
pubmed: 31910710
Immunol Rev. 2008 Dec;226:205-18
pubmed: 19161426
Cancer Immunol Res. 2014 Mar;2(3):194-9
pubmed: 24778315
Laryngoscope. 2016 Apr;126(4):885-93
pubmed: 26542064
Genet Mol Res. 2015 Feb 02;14(1):925-30
pubmed: 25730030
Immunol Lett. 2016 Sep;177:47-52
pubmed: 27474414
Immunol Res. 2010 Jul;47(1-3):185-206
pubmed: 20087682
Biomed Mater Eng. 2014;24(1):869-75
pubmed: 24211974
J Immunol Res. 2014;2014:149185
pubmed: 24901008
Eur J Cancer. 2015 Oct;51(15):2130-2143
pubmed: 26421817
BMC Cancer. 2010 Aug 24;10:456
pubmed: 20735825
J Laryngol Otol. 2007 Mar;121(3):246-52
pubmed: 17040593
Crit Rev Immunol. 2012;32(1):23-63
pubmed: 22428854
Int J Immunogenet. 2019 Feb;46(1):20-30
pubmed: 30430731
Postgrad Med J. 2018 May;94(1111):284-288
pubmed: 29487192
J Cancer Epidemiol. 2018 Jun 3;2018:9678097
pubmed: 29973955
J Intern Med. 2002 Sep;252(3):206-24
pubmed: 12270001
Cancer Gene Ther. 2015 Dec;22(12):554-63
pubmed: 26584531
Heliyon. 2020 Apr 03;6(4):e03728
pubmed: 32274439
Lancet Oncol. 2006 Feb;7(2):149-56
pubmed: 16455479
J Immunol. 2004 Sep 1;173(5):3215-22
pubmed: 15322183
Yonago Acta Med. 2014 Jun;57(2):65-72
pubmed: 25324587
J Laryngol Otol. 2016 Jan;130(1):8-14
pubmed: 26585180
CA Cancer J Clin. 2017 Jan;67(1):31-50
pubmed: 27898173
Oncol Lett. 2014 May;7(5):1721-1727
pubmed: 24765208
Int J Cancer. 1993 Aug 19;55(1):96-101
pubmed: 8344757
Cancer Lett. 2002 Oct 8;184(1):57-63
pubmed: 12104048
Ann Oncol. 2013 Dec;24(12):3107-12
pubmed: 24121119
IUBMB Life. 2017 Jul;69(7):522-527
pubmed: 28474494
Genet Mol Res. 2016 Jun 03;15(2):
pubmed: 27323141
PLoS One. 2012;7(3):e33628
pubmed: 22438968
Int J Clin Exp Pathol. 2020 Mar 01;13(3):573-581
pubmed: 32269698
Annu Rev Immunol. 2001;19:683-765
pubmed: 11244051
Turk J Med Sci. 2019 Feb 11;49(1):123-128
pubmed: 30762321
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
Am J Pathol. 1998 Oct;153(4):1229-37
pubmed: 9777954
Semin Immunol. 2006 Jun;18(3):151-8
pubmed: 16730454
FASEB J. 2013 Jun;27(6):2496-503
pubmed: 23430974
Immunol Rev. 2008 Dec;226:219-33
pubmed: 19161427
PLoS One. 2012;7(7):e39868
pubmed: 22859944
Int J Cancer. 1994 Mar 1;56(5):755-60
pubmed: 8314354
Sci Rep. 2015 Nov 27;5:17149
pubmed: 26612133
J Immunol. 2006 Aug 15;177(4):2565-74
pubmed: 16888018
J Diabetes Metab Disord. 2018 Sep 1;17(2):333-343
pubmed: 30918869
Oral Dis. 2019 Sep;25(6):1619-1626
pubmed: 31055876
J Natl Compr Canc Netw. 2020 Jul;18(7):873-898
pubmed: 32634781
J Exp Med. 2005 Sep 5;202(5):583-8
pubmed: 16129707
Anticancer Res. 2004 Sep-Oct;24(5C):3387-92
pubmed: 15515436
Acta Otorhinolaryngol Ital. 2017 Dec;37(6):458-466
pubmed: 28663597